22283-43-8

Usage

Uses

Used in Research and Experimental Procedures:
1-[4-(Dimethylamino)phenyl]-2-thiourea is used as a chemical compound for research and experimental purposes. Its specific applications aren't extensively documented in the public domain because of its specialized usage in scientific studies. 1-[4-(DIMETHYLAMINO)PHENYL]-2-THIOUREA's properties, reactivity, and safety precautions must be analyzed and understood to ensure proper handling and application in research settings.

InChI:InChI=1/C9H13N3S/c1-12(2)8-5-3-7(4-6-8)11-9(10)13/h3-6H,1-2H3,(H3,10,11,13)

Upstream product

• 6281-64-7 N-benzoyl-N'-(4-dimethylamino-phenyl)-thiourea 
• 1147550-11-5 ammonium thiocyanate 
• 536-46-9 4-dimethylaminophenylamine dihydrochloride 
• 2131-64-8 4-isothiocyanato-N,N-dimethylaniline 
• 99-98-9 4-amino-N,N-dimethylaniline 
• 532-55-8 Benzoyl isothiocyanate 
• 2052-46-2 N,N-dimethyl-p-phenylenediamine hydrochloride 

Downstream Products

• 146680-41-3 4-Anilino-2-(4-dimethylaminophenyl)imino-5-phenylimino-Δ³-thiazolin 
• 65069-82-1 1-(4-Dimethylamino-phenyl)-2-methyl-isothiourea; hydriodide 
• 315705-02-3 N2-(4-(dimethylamino)phenyl)-4′-methyl-[4,5′-bithiazole]-2,2′-diamine 
• 315704-51-9 N-(2-((4-(dimethylamino)phenyl)amino)-4′-methyl-[4,5′-bithiazol]-2′-yl)propionamide 
• 65070-18-0 N-(4-Dimethylamino-phenyl)-piperidine-1-carboxamidine 

Relevant academic research and scientific papers

Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases

Enteroviruses (EVs) are among the most frequent infectious agents in humans worldwide and represent the leading cause of upper respiratory tract infections. No drugs for the treatment of EV infections are currently available. Recent studies have also linked EV infection with pulmonary exacerbations, especially in cystic fibrosis (CF) patients, and the importance of this link is probably underestimated. The aim of this work was to develop a new class of multitarget agents active both as broad-spectrum antivirals and as correctors of the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding defect responsible for >90% of CF cases. We report herein the discovery of the first small molecules able to simultaneously act as correctors of the F508del-CFTR folding defect and as broad-spectrum antivirals against a panel of EVs representative of all major species.

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

Aminothiazole compound, and preparation method and application thereof

The invention discloses an aminothiazole compound, and a preparation method and an application thereof. The compound has a following structural formula. In the formula, n, m, x are all 0 or 1, and only one of the three is 1 or the three are 0 at a same time; R1 is hydrogen, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, 2-pyrazinyl, 2-furyl, 2-thienyl, 2-pyrrolyl, 2-quinolyl, or 2-methylenepyridine; R2 is hydrogen or alkane with 1-10 aliphatic carbon chains; R3 or R4 is hydrogen or as the picture; R5 is hydrogen, a structure as the picture, N,N-diethyl, N,N-dipropyl, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy or cyano; among R3, R4 and R5, two are hydrogen at a same time; R6 and R7 can be same or different, and can be H, alkane with 1-10 aliphatic carbon chains, olefin or alkyne. In animal bodies, the compounds can inhibit the proliferation and growth of KRAS high mutant tumors such as pancreatic cancer and colon cancer.

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2-yl)-(2,4′-bithiazol)-2′-amine (24, ST-1803; IC50values: 7.3 μM (SphK1), 6.5 μM (SphK2)) as a promising candidate for further in vivo investigations and structural development.

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.

Substituted N-phenylisothioureas: Potent inhibitors of human nitric oxide synthase with neuronal isoform selectivity

S-Ethyl N-phenylisothiourea (4) has been found to be a potent inhibitor of both the human constitutive and inducible isoforms of nitric oxide synthase. A series of substituted N-phenylisothiourea analogues was synthesized to investigate the structure-activity relationship of this class of inhibitor. Each analogue was evaluated for human isoform selectivity. One analogue, S-ethyl N-[4-(trifluoromethyl)phenyl]isothiourea (39), exhibited 115-fold and 29-fold selectivity for the neuronal isoform versus the inducible and endothelial derived constitutive isoforms, respectively. Studies have shown the substituted N-phenylisothiourea 39 binds competitively with L,-arginine.

Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas

An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N'-benzoylthioureas with 5percent aqueous sodium hydroxide.Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g. 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.